End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
35.79 CNY | -1.84% | +1.16% | +6.36% |
05-15 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes | CI |
04-30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The firm trades with high earnings multiples: 23.49 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.36% | 3.35B | C | ||
+42.38% | 6.28B | B- | ||
-15.86% | 4.51B | C+ | ||
-11.28% | 3.13B | B- | ||
-3.23% | 2.47B | - | D+ | |
+45.24% | 1.96B | - | ||
-7.89% | 1.68B | - | - | |
-0.98% | 1.63B | - | - | |
-11.32% | 1.56B | C- | ||
+47.00% | 1.53B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600329 Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited